Skip to main content
. 2017 Mar 2;12(3):e0172412. doi: 10.1371/journal.pone.0172412

Fig 5. Treatment with human PBMCs with depletion of type I NKT cells.

Fig 5

HCV-infected human hepatocyte chimeric mice were injected with whole human PBMCs or type 1 NKT-depleted human PBMCs (n = 3), and then treated with (n = 6) or without (n = 4) 1000 IU/kg of IFN-α for seven days. (a) Reduction of serum HCV RNA levels (upper panel) and human albumin concentrations (lower panel) are shown. IFN-α treated mice without human PBMC transplantation were also analyzed. Data are presented as the mean ± SD. (b) Liver mononuclear cells isolated from mice seven days after human PBMC treatment were stained with antibodies against human CD45 and mouse CD45, and analyzed by flow cytometry (upper panel). Statistical analysis of the frequencies of human mononuclear cells in PBMCs-treated mice is shown in the lower panel. Data are presented as the mean ± SD.